{"analyses":[{"ciLowerLimit":"0.093","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.371","estimateComment":"The HR and 95% CI were estimated from a stratified Cox proportional hazards model.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<.0001","pValueComment":"The 2-sided nominal p-value was calculated based on a stratified log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"0.186","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The median event rate was not reached, and the upper limit of the 95% confidence interval could not be estimated due to insufficient number of events beyond the median at time of data cutoff.","groupId":"OG000","lowerLimit":"35.19","upperLimit":"NA","value":"NA"},{"comment":"The median event rate was not reached, and the upper limit of the 95% confidence interval could not be estimated due to insufficient number of events beyond the median at time of data cutoff.","groupId":"OG001","lowerLimit":"33.38","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"141"}],"units":"Participants"}],"description":"PFS, as assessed by investigator, is defined as the time from randomization until documented disease progression as per iwCLL (International Workshop on Chronic Lymphocytic Leukemia) 2018 criteria, or death from any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pirtobrutinib 200 milligrams (mg) orally once daily in continuous 28-day cycles until disease progression or unacceptable toxicity.","id":"OG000","title":"Arm A - Pirtobrutinib"},{"description":"Participants received bendamustine 90 milligrams per square meter (mg/m²) intravenously on Days 1 and 2 of each 28-day cycle (Cycles 1-6) plus rituximab 375 mg/m² intravenously on Cycle 1 Day 1, then 500 mg/m² on Day 1 of Cycles 2-6. Eligible participants in Arm B crossed over to receive pirtobrutinib following independent review committee (IRC)-confirmed progressive disease (PD).","id":"OG001","title":"Arm B - Bendamustine Plus Rituximab"}],"paramType":"MEDIAN","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"From randomization until documented disease progression or death (up to 40 months)","title":"Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"Months"}